Distinguished in Gliosarcoma

Dr. Jeremy D. Rudnick

Neurology
Cedars-Sinai Medical Care Foundation
3400 Lomita Blvd, Suite 104, 
Torrance, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Gliosarcoma
Cedars-Sinai Medical Care Foundation
3400 Lomita Blvd, Suite 104, 
Torrance, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeremy Rudnick is a Neurologist in Torrance, California. Dr. Rudnick is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Gliosarcoma.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CA
Hospital Affiliations
Torrance Memorial Medical Center
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

CEDARS-SINAI MEDICAL CARE FOUNDATION
3400 Lomita Blvd, Suite 104, Torrance, CA 90505
Other Locations
CEDARS-SINAI MEDICAL CENTER
8700 Beverly Blvd, West Hollywood, CA 90048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Procedure, Device
Study Drug: Tozuleristide
Study Phase: Phase 2
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Radiation, Procedure
Study Phase: Early Phase 1
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
Enrollment Status: Withdrawn
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Tucatinib, Pembrolizumab, Trastuzumab
Study Phase: Phase 1/Phase 2
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma
Enrollment Status: Terminated
Publish Date: November 20, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

17 Total Publications

A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma.
A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma.
Journal: Scientific reports
Published: March 25, 2024
Similar Doctors
Elite in Gliosarcoma
Dr. Santosh Kesari
Neurology
Elite in Gliosarcoma
Dr. Santosh Kesari
Neurology
2121 Santa Monica Boulevard, 
Santa Monica, CA 
 (17.0 miles away)
310-829-5511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Santosh Kesari is a Neurologist in Santa Monica, California. Dr. Kesari is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy. Dr. Kesari is currently accepting new patients.

Elite in Gliosarcoma
Dr. Timothy Cloughesy
Neurology | Hematology Oncology
Elite in Gliosarcoma
Dr. Timothy Cloughesy
Neurology | Hematology Oncology

The Regents Of The University Of California

100 Medical Plz, Suite 425, 
Los Angeles, CA 
 (18.4 miles away)
310-794-1500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Cloughesy is a Neurologist and a Hematologist Oncology provider in Los Angeles, California. Dr. Cloughesy is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Distinguished in Gliosarcoma
Dr. Surasak Phuphanich
Neurology | Oncology
Distinguished in Gliosarcoma
Dr. Surasak Phuphanich
Neurology | Oncology
8700 Beverly Blvd, 
West Hollywood, CA 
 (18.4 miles away)
310-423-5000
Languages Spoken:
English
See accepted insurances

Surasak Phuphanich is a Neurologist and an Oncologist in West Hollywood, California. Dr. Phuphanich is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliosarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rudnick's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile